An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme.

TPS2078 Background: Post-resected glioblastoma multiforme (GMB) patients were treated with dodecafluoropentane emulsion (DDFPe) to evaluate the pharmacokinetics (PK), safety and potential survival benefit in combination with the current standard of care: radiation therapy (RT) and temozolomide (TMZ). DDFPe is an oxygen transport agent, which carries more than 100x more oxygen than other tested fluorocarbons. Studies in tumor xenografts show that DDFPe increases tumor pO2 by up to 400% and mitigates radiation resistance (J Biomed Nanotechnology, Vol 11, No 2, Feb2015, pp. 274-281). Methods: DDFPe is being dosed using an accelerated escalation design with one patient per dose level. Eligible patients have previously-untreated GBM with residual enhancing tumor on an early post-operative MRI scan, ECOG score 0-2, satisfactory blood counts and adequate renal and hepatic function. Since an increase in the frequency and extent of radiation necrosis is a theoretical risk of increased oxygenation, the location and...